NCT01957579 2017-06-12A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell MalignanciesAstraZenecaPhase 1 Completed32 enrolled 23 charts
NCT01466153 2017-05-31A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)MedImmune LLCPhase 2 Completed183 enrolled 17 charts